Article
Assessment of Minimal Residual Disease in Standard-Risk AML.
The New England journal of medicine - 4 Feb 2016
Ivey Adam, Hills Robert K, Simpson Michael A, Jovanovic Jelena V, Gilkes Amanda, Grech Angela, Patel Yashma, Bhudia Neesa, Farah Hassan, Mason Joanne, Wall Kerry, Akiki Susanna, Griffiths Michael, Solomon Ellen, McCaughan Frank, Linch David C, Gale Rosemary E, Vyas Paresh, Freeman Sylvie D, Russell Nigel, Burnett Alan K, Grimwade David
Abstract excerpt
BACKGROUND: Despite the molecular heterogeneity of standard-risk acute myeloid leukemia (AML), treatment decisions are based on a limited number of molecular genetic markers and morphology-based assessment of remission. Sensitive detection of a leukemia-specific marker (e.g., a mutation in the gene encoding nucleophosmin [NPM1]) could improve prognostication by identifying submicroscopic disease during remission....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.